Chapter 66 Immunotherapy

  1. Hoption Cann SA, van Netten JP, van Netten C: Dr William Coley and tumour regression: a place in history or in the future. Postgrad Med J 79:672, 2003. PUBMED Abstract
  2. Hadden JW: Immunostimulants. Immunol Today 14:275, 1993. PUBMED Abstract
  3. Van Kampen KR: Immunotherapy and cytokines. Semin Vet Med Surg (Small Anim) 12:186, 1997. PUBMED Abstract
  4. Longworth KE: The comparative biology of pulmonary intravascular macrophages. Front Biosci 2:d232, 1997. PUBMED Abstract
  5. Parbhakar OP, Duke T, Townsend HG, et al: Immunophenotypic characterization and depletion of pulmonary intravascular macrophages of horses. Vet Res 35:39, 2004. PUBMED Abstract
  6. Andreakos E, Foxwell B, Feldmann M: Is targeting toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? Immunol Rev 202:250, 2004. PUBMED Abstract
  7. Alarco AM, Marcil A, Chen J, et al: Immune-deficient Drosophila melanogaster: a model for the innate immune response to human fungal pathogens. J Immunol 172:5622, 2004. PUBMED Abstract
  8. Netea MG, Van der Graaf C, Van der Meer JW, et al: Recognition of fungal pathogens by toll-like receptors. Eur J Clin Microbiol Infect Dis 23:672, 2004. PUBMED Abstract
  9. O'Neill LA: TLRs: Professor Mechnikov, sit on your hat. Trends Immunol 25:687, 2004. PUBMED Abstract
  10. Smyth MJ, Cretney E, Kershaw MH, et al: Cytokines in cancer immunity and immunotherapy. Immunol Rev 202:275, 2004. PUBMED Abstract
  11. Cox WI: Examining the immunologic and hematopoietic properties of an immunostimulant. Vet Med 6:424, 1988.
  12. Rossol S, Voth R, Brunner S: Corynebacterium parvum (Propionibacterium acnes): an inducer of tumor necrosis factor-alpha in human peripheral blood mononuclear cells and monocytes in vitro. Eur J Immunol 20:1761, 1990. PUBMED Abstract
  13. Walters CE, Ingham E, Eady EA, et al: In vitro modulation of keratinocyte-derived interleukin-1 alpha (IL-1 alpha) and peripheral blood mononuclear cell-derived IL-1 beta release in response to cutaneous commensal microorganisms. Infect Immun 63:1223, 1995. PUBMED Abstract
  14. Mantovani A, Dean JH, Jerrells TR, et al: Augmentation of tumoricidal activity of human monocytes and macrophages by lymphokines. Int J Cancer 25:691, 1980. PUBMED Abstract
  15. Kim J, Ochoa MT, Krutzik SR, et al: Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol 169:1535, 2002. PUBMED Abstract
  16. Cervi L, MacDonald AS, Kane C, et al: Cutting edge: dendritic cells copulsed with microbial and helminth antigens undergo modified maturation, segregate the antigens to distinct intracellular compartments, and concurrently induce microbe-specific Th1 and helminth-specific Th2 responses. J Immunol 72:2016, 2004. PUBMED Abstract
  17. Kalis C, Gumenscheimer M, Freudenberg N, et al: Requirement for TLR9 in the immunomodulatory activity of Propionibacterium acnes. J Immunol 174:4295, 2005. PUBMED Abstract
  18. Squaiella CC, Ananias RZ, Mussalem JS, et al: In vivo and in vitro effect of killed Propionibacterium acnes and its purified soluble polysaccharide on mouse bone marrow stem cells and dendritic cell differentiation. Immunobiology 211:105, 2006. PUBMED Abstract
  19. Flaminio MJ, Rush BR, Shuman W: Immunologic function in horses after non-specific immunostimulant administration. Vet Immunol Immunopathol 63:303, 1998. PUBMED Abstract
  20. Davis EG, Rush BR, Blecha F: Increases in cytokine and antimicrobial peptide gene expression in horses by immunomodulation with Propionibacterium acnes. Vet Ther 4:5, 2003. PUBMED Abstract
  21. Nevsted A: Evaluation of an immunostimulant in preventing shipping stress related respiratory disease. J Equine Vet Sci 16:78, 1996.
  22. Evans DR, Rollins JB, Huff GK, et al: Inactivated Propionibacterium acnes (ImmunoRegulin) as adjunct to conventional therapy in the treatment of equine respiratory diseases. Equine Pract 10:17, 1988.
  23. Sturgill TL, Horohov DW: Vaccination response of young foals to keyhole limpet hemocyanin: evidence of effective priming in the presence of maternal antibodies. J Eq Vet Sc 30:359, 2010.
  24. Ryan C, Giguère S, Fultz L, et al: Effects of two commercially available immunostimulants on leukocyte function of foals following ex vivo exposure to Rhodococcus equi. Vet Immunol Immunopathol 138:198, 2010. PUBMED Abstract
  25. Mackaness GB, Auclair DJ, Iagrange PH: Immunopotentiation with BCG immune response to different strains and preparations. J Natl Cancer Inst 5:1655, 1973. PUBMED Abstract
  26. Morales A, Eidinger D, Bruce AW: Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumours. J Urol 116:180, 1976. PUBMED Abstract
  27. Meyer JP, Persad R, Gillatt DA: Use of bacille Calmette-Guérin in superficial bladder cancer. Postgrad Med J 78:449, 2002. PUBMED Abstract
  28. Dennehy M, Williamson AL: Factors influencing the immune response to foreign antigen expressed in recombinant BCG vaccines. Vaccine 23:1209, 2005. PUBMED Abstract
  29. Nicolle D, Fremond C, Pichon X: Long-term control of Mycobacterium bovis BCG infection in the absence of toll-like receptors (TLRs): investigation of TLR2-, TLR6-, or TLR2-TLR4-deficient mice. Infect Immun 72:6994, 2004. PUBMED Abstract
  30. Takeuchi O, Sato S, Horiuchi T: Cutting edge: role of toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 169:10, 2002. PUBMED Abstract
  31. Koh YI, Choi IS, Lee JJ: Effects of cytokine milieu secreted by BCG-treated dendritic cells on allergen-specific Th immune response. J Korean Med Sci 19:640, 2004. PUBMED Abstract
  32. Suttmann H, Jacobsen M, Reiss K, et al: Mechanisms of bacillus Calmette-Guérin mediated natural killer cell activation. J Urol 172:1490, 2004. PUBMED Abstract
  33. Esin S, Batoni G, Pardini M, et al: Functional characterization of human natural killer cells responding to Mycobacterium bovis bacille Calmette-Guérin. Immunology 112:143, 2004. PUBMED Abstract
  34. Suttmann H, Lehan N, Bohle A, et al: Stimulation of neutrophil granulocytes with Mycobacterium bovis bacillus Calmette-Guérin induces changes in phenotype and gene expression and inhibits spontaneous apoptosis. Infect Immun 71:4647, 2003. PUBMED Abstract
  35. Cormack S, Alkemade S: Clinical study evaluating a purified mycobacterial cell wall extract for the treatment of equine respiratory disease. Equine Pract 13:18, 1991.
  36. Owen RA, Jagger DW: Clinical observations on the use of BCG cell wall fraction for treatment of periocular and other equine sarcoids. Vet Rec 120:548, 1987. PUBMED Abstract
  37. Klein WR, Bras GE, Misdorp W: Equine sarcoid: BCG immunotherapy compared to cryosurgery in a prospective randomised clinical trial. Cancer Immunol Immunother 21:133, 1986. PUBMED Abstract
  38. Dourado I, Rios MH, Pereira SM, et al: Rates of adverse reactions to first and second doses of BCG vaccination: results of a large community trial in Brazilian schoolchildren. Int J Tuberc Lung Dis 7:399, 2003. PUBMED Abstract
  39. Chang H, Klein JS, Norotsky M, et al: Granulomatous chest disease following intravesical bacillus Calmette-Guérin immunotherapy. J Thorac Imaging 19:60, 2004. PUBMED Abstract
  40. Peyriere H, Klouche K, Beraud JJ, et al: Fatal systemic reaction after multiple doses of intravesical bacillus Calmette-Guérin for polyposis. Ann Pharmacother 34:1279, 2000. PUBMED Abstract
  41. De Diego A, Rogado MC, Prieto M: Disseminated pulmonary granulomas after intravesical bacillus Calmette-Guérin immunotherapy. Respiration 64:304, 1997. PUBMED Abstract
  42. Viel L, Kenney D: Suspect adverse pulmonary reactions to Equimune I.V. in four horses presented to the Ontario Veterinary College (OVC). In Proc 12th Vet Respir Symp, 1993.
  43. van den Boom R, Veldhuis Kroeze EJ, Klein WR, et al: Granulomatous pneumonia, lymphadenopathy, and hepatopathy in an adult horse with repeated injection of BCG. J Vet Intern Med 22:1056, 2008. PUBMED Abstract
  44. Krieg AM: CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709, 2002. PUBMED Abstract
  45. Krieg AM, Yi AK, Hartmann G: Mechanisms and therapeutic applications of immune stimulatory cpG DNA. Pharmacol Ther 84:113, 1999. PUBMED Abstract
  46. Ishii KJ, Gursel I, Gursel M, et al: Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleotides. Curr Opin Mol Ther 6:166, 2004. PUBMED Abstract
  47. Mutwiri G, Pontarollo R, Babiuk S, et al: Biological activity of immunostimulatory CpG DNA motifs in domestic animals. Vet Immunol Immunopathol 91:89, 2003. PUBMED Abstract
  48. Kline JN, Waldschmidt TJ, Businga TR, et al: Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol 160:2555, 1998. PUBMED Abstract
  49. He B, Qiao X, Cerutti A: CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. J Immunol 173:4479, 2004. PUBMED Abstract
  50. Brunner C, Seiderer J, Schlamp A, et al: Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J Immunol 165:6278, 2000. PUBMED Abstract
  51. Hartmann G, Weiner GJ, Krieg AM: CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci USA 96:9305, 1999. PUBMED Abstract
  52. Kandimalla ER, Bhagat L, Wang D: Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles. Nucleic Acids Res 31:2393, 2003. PUBMED Abstract
  53. Rankin R, Pontarollo R, Ioannou X, et al: CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev 11:333, 2001. PUBMED Abstract
  54. Kandimalla ER, Bhagat L, Zhu FG, et al: A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif. Proc Natl Acad Sci USA 100:14303, 2003. PUBMED Abstract
  55. Liu T, Nerren J, Liu M, et al: Basal and stimulus-induced cytokine expression is selectively impaired in peripheral blood mononuclear cells of newborn foals. Vaccine 27:674, 2009. PUBMED Abstract
  56. Liu M, Liu T, Bordin A, et al: Activation of foal neutrophils at different ages by CpG oligodeoxynucleotides and Rhodococcus equi. Cytokine 48:280, 2009. PUBMED Abstract
  57. Bordin AI, Liu M, Nerren JR, et al: Neutrophil function of neonatal foals is enhanced in vitro by CpG oligodeoxynucleotide stimulation. Vet Immunol Immunopathol 145:290–297, 2012. PUBMED Abstract
  58. Liu M, Bordin A, Liu T, et al: Gene expression of innate Th1-, Th2-, and Th17-type cytokines during early life of neonatal foals in response to Rhodococcus equi. Cytokine 56:356, 2011. PUBMED Abstract
  59. Flaminio MJ, Borges AS, Nydam DV, et al: The effect of CpG-ODN on antigen presenting cells of the foal. J Immune Based Ther Vaccines 5:1, 2007. PUBMED Abstract
  60. Lopez AM, Hines MT, Palmer GH, et al: Analysis of anamnestic immune responses in adult horses and priming in neonates induced by a DNA vaccine expressing the vapA gene of Rhodococcus equi. Vaccine 21:3815, 2003. PUBMED Abstract
  61. Klier J, May A, Fuchs S, et al: Immunostimulation of bronchoalveolar lavage cells from recurrent airway obstruction-affected horses by different CpG-classes bound to gelatin nanoparticles. Vet Immunol Immunopathol 144:79, 2011. PUBMED Abstract
  62. Cornelie S, Wiel E, Lund N: Cytosine-phosphate-guanine (CpG) motifs are sensitizing agents for lipopolysaccharide in toxic shock model. Intensive Care Med 28:1340, 2002. PUBMED Abstract
  63. Staeheli P, Sentandreu M, Pagenstecher A, et al: Alpha/beta interferon promotes transcription and inhibits replication of Borna disease virus in persistently infected cells. J Virol 75:8216, 2001. PUBMED Abstract
  64. Biron CA: Interferons alpha and beta as immune regulators: a new look. Immunity 14:661, 2001. PUBMED Abstract
  65. Malmgaard L: Induction and regulation of IFNs during viral infections. J Interferon Cytokine Res 24:439, 2004. PUBMED Abstract
  66. Atreya PL, Kulkarni S: Respiratory syncytial virus strain A2 is resistant to the antiviral effects of type I interferons and human MxA. Virology 261:227, 1999. PUBMED Abstract
  67. Freudenberg MA, Merlin T, Kalis C, et al: Cutting edge: a murine, IL-12-independent pathway of IFN-gamma induction by gram-negative bacteria based on STAT4 activation by type I IFN and IL-18 signaling. J Immunol 169:1665, 2002. PUBMED Abstract
  68. Nguyen KB, Salazar-Mather TP, Dalod MY, et al: Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection. J Immunol 169:4279, 2002. PUBMED Abstract
  69. Ellis TN, Beaman BL: Interferon-gamma activation of polymorphonuclear neutrophil function. Immunology 112:2, 2004. PUBMED Abstract
  70. Takasu H: Interferon-alpha: an effective adjuvant for peptide-based cytotoxic T-cell vaccines. Kurume Med J 48:171, 2001. PUBMED Abstract
  71. Cacoub P, Saadoun D, Limal N, et al: PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus–related systemic vasculitis. Arthritis Rheum 52:911, 2005. PUBMED Abstract
  72. Anderson JF, Rahal JJ: Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro. Emerg Infect Dis 8:107, 2002. PUBMED Abstract
  73. Huber CH, Wolfel T: Immunotherapy of cancer: from vision to standard clinical practice. J Cancer Res Clin Oncol 130:367, 2004. PUBMED Abstract
  74. Burchert A, Neubauer A: Interferon alpha and T-cell responses in chronic myeloid leukemia. Leuk Lymphoma 46:167, 2005. PUBMED Abstract
  75. Krown SE: Management of Kaposi sarcoma: the role of interferon and thalidomide. Curr Opin Oncol 13:374, 2001. PUBMED Abstract
  76. Guo JT, Hayashi J, Seeger C: West Nile virus inhibits the signal transduction pathway of alpha interferon. J Virol 79:1343, 2005. PUBMED Abstract
  77. Kalil AC, Devetten MP, Singh S, et al: Use of interferon-alpha in patients with West Nile encephalitis: report of 2 cases. Clin Infect Dis 40:764, 2005. PUBMED Abstract
  78. Lukaszewski RA, Brooks TJ: Pegylated alpha interferon is an effective treatment for virulent Venezuelan equine encephalitis virus and has profound effects on the host immune response to infection. J Virol 74:5006, 2000. PUBMED Abstract
  79. Liu G, Zhai Q, Schaffner DJ, et al: Prevention of lethal respiratory vaccinia infections in mice with interferon-alpha and interferon-gamma. FEMS Immunol Med Microbiol 40:201, 2004. PUBMED Abstract
  80. Moore BR, Krakowka S, Cummins JM, et al: Changes in airway inflammatory cell populations in Standardbred racehorses after interferon-alpha administration. Vet Immunol Immunopathol 49:347, 1996. PUBMED Abstract
  81. Seahorn TL, Carter GK, Martens JG, et al: Effects of human alpha interferon on experimentally induced equine herpesvirus-1 infection in horses. Am J Vet Res 51:2006, 1990. PUBMED Abstract
  82. Moore I, Horney B, Day K, Lofstedt J, et al: Treatment of inflammatory airway disease in young Standardbreds with interferon alpha. Can Vet J 45:594, 2004. PUBMED Abstract
  83. O'Brien L, Perkins S, Williams A, et al: Alpha interferon as an adenovirus-vectored vaccine adjuvant and antiviral in Venezuelan equine encephalitis virus infection. J Gen Virol 90:874, 2009. PUBMED Abstract
  84. Smyth MJ, Cretney E, Kershaw MH, et al: Cytokines in cancer immunity and immunotherapy. Immunol Rev 202:275, 2004. PUBMED Abstract
  85. Eklund JW, Kuzel TM: A review of recent findings involving interleukin-2-based cancer therapy. Curr Opin Oncol 16:542, 2004. PUBMED Abstract
  86. Mitchell MS: Combinations of anticancer drugs and immunotherapy. Cancer Immunol Immunother 52:686, 2003. PUBMED Abstract
  87. Dillman R, Schiltz P, DePriest C, et al: Tumor-infiltrating lymphocytes and interleukin-2: dose and schedules of administration in the treatment of metastatic cancer. Cancer Biother Radiopharm 19:730, 2004. PUBMED Abstract
  88. Chen YM, Ting CC, Peng JW, et al: Restoration of cytotoxic T lymphocyte function in malignant pleural effusion: interleukin-15 vs. interleukin-2. J Interferon Cytokine Res 20:31, 2000. PUBMED Abstract
  89. Bermudez LE, Petrofsky M, Wu M, et al: Clarithromycin significantly improves interleukin-12-mediated anti-Mycobacterium avium activity and abolishes toxicity in mice. J Infect Dis 178:896, 1998. PUBMED Abstract
  90. Pammit MA, Budhavarapu VN, Raulie EK, et al: Intranasal interleukin-12 treatment promotes antimicrobial clearance and survival in pulmonary Francisella tularensis subsp. novicida infection. Antimicrob Agents Chemother 48:4513, 2004. PUBMED Abstract
  91. Tsurita M, Kurokawa M, Imakita M, et al: Early augmentation of interleukin (IL)-12 level in the airway of mice administered orally with clarithromycin or intranasally with IL-12 results in alleviation of influenza infection. J Pharmacol Exp Ther 298:362, 2001. PUBMED Abstract
  92. Clemons KV, Brummer E, Stevens DA: Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis. Antimicrob Agents Chemother 38:460, 1994. PUBMED Abstract
  93. Kim TS, DeKruyff RH, Rupper R, et al: An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1–dominated immune response and inhibiting antigen-specific IgE production. J Immunol 158:4137, 1997. PUBMED Abstract
  94. Walter DM, Wong CP, DeKruyff RH, et al: IL-18 gene transfer by adenovirus prevents the development of and reverses established allergen-induced airway hyperreactivity. J Immunol 166:6392, 2001. PUBMED Abstract
  95. Heinzerling LM, Feige K, Rieder S, et al: Tumor regression induced by intratumoral injection of DNA coding for human interleukin 12 into melanoma metastases in gray horses. J Mol Med 78:692, 2001. PUBMED Abstract
  96. Müller J, Feige K, Wunderlin P, et al: Double-blind placebo-controlled study with interleukin-18 and interleukin-12-encoding plasmid DNA shows antitumor effect in metastatic melanoma in gray horses. J Immunother 34:58, 2011. PUBMED Abstract
  97. Murphey ED, Herndon DN, Sherwood ER: Gamma interferon does not enhance clearance of Pseudomonas aeruginosa but does amplify a proinflammatory response in a murine model of postseptic immunosuppression. Infect Immun 72:6892, 2004. PUBMED Abstract
  98. Vollstedt S, Franchini M, Hefti HP, et al: Flt3 ligand–treated neonatal mice have increased innate immunity against intracellular pathogens and efficiently control virus infections. J Exp Med 197:575, 2003. PUBMED Abstract
  99. Kohn CW, Swardson C, Provost P: Myeloid and megakaryocytic hypoplasia in related Standardbreds. J Vet Intern Med 9:315, 1995. PUBMED Abstract
  100. Davis EG, Rush B, Bain F, et al: Neonatal neutropenia in an Arabian foal. Equine Vet J 35:517, 2003. PUBMED Abstract
  101. Buttner M, Czerny CP, Lehner KH, et al: Interferon induction in peripheral blood mononuclear leukocytes of man and farm animals by poxvirus vector candidates and some poxvirus constructs. Vet Immunol Immunopathol 46:237, 1995. PUBMED Abstract
  102. Friebe A, Siegling A, Friederichs S, et al: Immunomodulatory effects of inactivated parapoxvirus ovis (ORF virus) on human peripheral immune cells: induction of cytokine secretion in monocytes and Th1-like cells. J Virol 78:9400, 2004. PUBMED Abstract
  103. Weber O, Siegling A, Friebe A, et al: Inactivated parapoxvirus ovis (Orf virus) has antiviral activity against hepatitis B virus and herpes simplex virus. J Gen Virol 84:1843, 2003. PUBMED Abstract
  104. Lindner A, von Wittke P, Thein P, et al: Effect of a paramunity inducer on the incidence of diseases and the plasma cortisol content in Thoroughbred foals before and after weaning. Tierarztl Prax 21:47, 1993. PUBMED Abstract
  105. Ziebell KL, Steinmann H, Kretzdorn D, et al: The use of Baypamun N in crowding associated infectious respiratory disease: efficacy of Baypamun N (freeze dried product) in 4-10 month old horses. Zentralbl Veterinarmed B 44:529, 1997. PUBMED Abstract
  106. Sturgill TL, Giguère S, Franklin RP, et al: Effects of inactivated parapoxvirus ovis on the cumulative incidence of pneumonia and cytokine secretion in foals on a farm with endemic infections caused by Rhodococcus equi. Vet Immunol Immunopathol 140:237, 2011. PUBMED Abstract
  107. Horohov DW, Breathnach CC, Sturgill TL, et al: In vitro and in vivo modulation of the equine immune response by parapoxvirus ovis. Equine Vet J 40:468, 2008. PUBMED Abstract
  108. Krakowski L, Krzyzanowski J, Wrona Z, et al: The effect of nonspecific immunostimulation of pregnant mares with 1,3/1,6 glucan and levamisole on the immunoglobulins levels in colostrum: selected indices of nonspecific cellular and humoral immunity in foals in neonatal and postnatal period. Vet Immunol Immunopathol 68:1, 1999. PUBMED Abstract
  109. Barker SA: The formation of aminorex in racehorses following levamisole administration. A quantitative and chiral analysis following synthetic aminorex or levamisole administration vs. aminorex-positive samples from the field: a preliminary report. J Vet Pharmacol Ther 32:160, 2009. PUBMED Abstract
  110. Hamm D, Willeford KO, White G, et al: Caprine serum fraction immunomodulator as supplemental treatment of lower respiratory disease in the horse. Equine Vet J 34:71, 2002. PUBMED Abstract
  111. Zhang L, Tizard IR: Activation of a mouse macrophage cell line by acemannan: the major carbohydrate fraction from Aloe vera gel. Immunopharmacology 35:119, 1996. PUBMED Abstract
  112. Stuart RW, Lefkowitz DL, Lincoln JA, et al: Upregulation of phagocytosis and candidicidal activity of macrophages exposed to the immunostimulant acemannan. Int J Immunopharmacol 19:75, 1997. PUBMED Abstract
  113. Torres SM, Malone ED, White SD, et al: The efficacy of imiquimod 5% cream (Aldara® in the treatment of aural plaque in horses: a pilot open-label clinical trial. Vet Dermatol 21:503, 2010. PUBMED Abstract
  114. O'Neill W, McKee S, Clarke AF: Immunological and haematinic consequences of feeding a standardised Echinacea (Echinacea angustifolia) extract to healthy horses. Equine Vet J 34:222, 2002. PUBMED Abstract
  115. Pearson W, Omar S, Clarke AF: Low-dose ginseng (Panax quinquefolium) modulates the course and magnitude of the antibody response to vaccination against equid herpesvirus I in horses. Can J Vet Res 71:213, 2007. PUBMED Abstract
  116. Babiuk LA, Babiuk SL, Baca-Estrada ME: Novel vaccine strategies. Adv Virus Res 58:29, 2002. PUBMED Abstract
  117. Macy DW: Vaccine adjuvants. Semin Vet Med Surg (Small Anim) 12:206, 1997. PUBMED Abstract
  118. Spickler AR, Roth JA: Adjuvants in veterinary vaccines: modes of action and adverse effects. J Vet Intern Med 17:273, 2003. PUBMED Abstract
  119. Lindblad EB: Aluminium compounds for use in vaccines. Immunol Cell Biol 82:497, 2004. PUBMED Abstract
  120. White RG: The adjuvant effect of microbial products on the immune response. Annu Rev Microbiol 30:579, 1976. PUBMED Abstract
  121. Causey RC, Artiushin SC, Crowley IF, et al: Immunisation of the equine uterus against Streptococcus equi subspecies zooepidemicus using an intranasal attenuated Salmonella vector. Vet J 184:156, 2010. PUBMED Abstract
  122. Patel GB, Sprott GD: Archaeobacterial ether lipid liposomes (archaeosomes) as novel vaccine and drug delivery systems. Crit Rev Biotechnol 19:317, 1999. PUBMED Abstract
  123. Jilek S, Merkle HP, Walter E: DNA-loaded biodegradable microparticles as vaccine delivery systems and their interaction with dendritic cells. Adv Drug Deliv Rev 57:377, 2005. PUBMED Abstract
  124. Anderson PW Jr, Stein EC, Insel RA: Background and indications for Haemophilus influenzae type b vaccines consisting of capsular antigen coupled to protein carriers. Contrib Microbiol Immunol 10:115, 1989. PUBMED Abstract
  125. Sanders MT, Brown LE, Deliyannis G, et al: ISCOM-based vaccines: the second decade. Immunol Cell Biol 83:119, 2005. PUBMED Abstract
  126. Heldens JG, Pouwels HG, Derks CG, et al: Duration of immunity induced by an equine influenza and tetanus combination vaccine formulation adjuvanted with ISCOM-Matrix. Vaccine 28:6989, 2010. PUBMED Abstract
  127. Flaminio MJ, Rush BR, Davis EG, et al: Characterization of peripheral blood and pulmonary leukocyte function in healthy foals. Vet Immunol Immunopathol 73:267, 2000. PUBMED Abstract
  128. Wilson WD, Mihalyi JE, Hussey S, et al: Passive transfer of maternal immunoglobulin isotype antibodies against tetanus and influenza and their effect on the response of foals to vaccination. Equine Vet J 33:644, 2001. PUBMED Abstract
  129. Minke JM, El-Hage CM, Tazawa P, et al: Evaluation of the response to an accelerated immunisation schedule using a canarypox-vectored equine influenza vaccine, shortened interdose intervals and vaccination of young foals. Aust Vet J 89(Suppl 1):137, 2011. PUBMED Abstract
  130. Potter AA, Babiuk LA: New approaches for antigen discovery, production and delivery: vaccines for veterinary and human use. Curr Drug Targets Infect Disord 1:249, 2001. PUBMED Abstract
  131. Van Kampen KR: Recombinant vaccine technology in veterinary medicine. Vet Clin North Am Small Anim Pract 31:535, 2001. PUBMED Abstract
  132. Van Drunen Littel-van den Hurk S, Babiuk SL, Babiuk LA: Strategies for improved formulation and delivery of DNA vaccines to veterinary target species. Immunol Rev 199:113, 2004. PUBMED Abstract
  133. Lunn DP, Soboll G, Schram BR, et al: Antibody responses to DNA vaccination of horses using the influenza virus hemagglutinin gene. Vaccine 17:2245, 1999. PUBMED Abstract
  134. Lopez AM, Hecker R, Mutwiri G, et al: Formulation with CpG ODN enhances antibody responses to an equine influenza virus vaccine. Vet Immunol Immunopathol 114:103, 2006. PUBMED Abstract
  135. Yannelli JR, Wroblewski JM: On the road to a tumor cell vaccine: 20 years of cellular immunotherapy. Vaccine 23:97, 2004. PUBMED Abstract
  136. Mocellin S, Mandruzzato S, Bronte V, et al: Part I. Vaccines for solid tumours. Lancet Oncol 5:681, 2004. PUBMED Abstract
  137. Bruno S: Follicular non-Hodgkin lymphomas and minimal residual disease. Medicina (B Aires) Suppl 2:77, 2000. PUBMED Abstract
  138. Liu M, Acres B, Balloul JM, et al: Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci USA 101(suppl 2):14567, 2004. PUBMED Abstract
  139. Hoos A, Levey DL, Lewis JJ: Autologous heat shock protein-peptide complexes for vaccination against cancer: from bench to bedside. Dev Biol (Basel) 116:109, 2004. PUBMED Abstract
  140. Okada H, Tsugawa T, Sato H, et al: Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines. Cancer Res 64:5830, 2004. PUBMED Abstract
  141. Markiewicz MA, Kast WM: Progress in the development of immunotherapy of cancer using ex vivo-generated dendritic cells expressing multiple tumor antigen epitopes. Cancer Invest 22:417, 2004. PUBMED Abstract
  142. Huggins JL, Looney RJ: Allergen immunotherapy. Am Fam Physician 70:689, 2004. PUBMED Abstract
  143. Till SJ, Francis JN, Nouri-Aria K: Mechanisms of immunotherapy. J Allergy Clin Immunol 113:1025, 2004. PUBMED Abstract
  144. Anderson GS, Belton P, Jahren E, et al: Immunotherapy trial for horses in British Columbia with Culicoides (Diptera: Ceratopogonidae) hypersensitivity. J Med Entomol 33:458, 1996. PUBMED Abstract
  145. Mueller RS, Veir J, Fieseler KV, et al: Use of immunostimulatory liposome–nucleic acid complexes in allergen-specific immunotherapy of dogs with refractory atopic dermatitis: a pilot study. Vet Dermatol 16:61, 2005. PUBMED Abstract
  146. McClure JT, DeLuca JL, Lunn DP, et al: Evaluation of IgG concentration and IgG subisotypes in foals with complete or partial failure of passive transfer after administration of intravenous serum or plasma. Equine Vet J 33:681, 2001. PUBMED Abstract
  147. Grondahl G, Johannisson A, Demmers S, et al: Influence of age and plasma treatment on neutrophil phagocytosis and CD18 expression in foals. Vet Microbiol 65:241, 1999. PUBMED Abstract
  148. Kohn CW, Knight D, Hueston W, et al: Colostral and serum IgG, IgA, and IgM concentrations in Standardbred mares and their foals at parturition. J Am Vet Med Assoc 195:64, 1989. PUBMED Abstract
  149. Lavoie JP, Spensley MS, Smith BP, et al: Absorption of bovine colostral immunoglobulins G and M in newborn foals. Am J Vet Res 50:1598, 1989. PUBMED Abstract
  150. Gröndahl G, Sternberg S, Jensen-Waern M, et al: Opsonic capacity of foal serum for the two neonatal pathogens Escherichia coli and Actinobacillus equuli. Equine Vet J 33:670, 2001. PUBMED Abstract
  151. Gardner RB, Nydam DV, Luna JA, et al: Serum opsonization capacity, phagocytosis and oxidative burst activity in neonatal foals in the intensive care unit. Journal of Veterinary Internal Medicine 21:797–805, 2007. PUBMED Abstract
  152. Grondahl G, Johannisson A, Jensen-Waern M: Opsonic effect of equine plasma from different donors. Vet Microbiol 56:227, 1997. PUBMED Abstract
  153. Madigan JE, Hietala S, Muller N: Protection against naturally acquired Rhodococcus equi pneumonia in foals by administration of hyperimmune plasma. J Reprod Fertil Suppl 44:571, 1991. PUBMED Abstract
  154. Giguere S, Gaskin JM, Miller C, et al: Evaluation of a commercially available hyperimmune plasma product for prevention of naturally acquired pneumonia caused by Rhodococcus equi in foals. J Am Vet Med Assoc 220:59, 2002. PUBMED Abstract
  155. Dawson DR, Nydam DV, Price CT, et al: Effects of opsonization of Rhodococcus equi on bacterial viability and phagocyte activation. Am J Vet Res 72:1465, 2011. PUBMED Abstract
  156. Forbes G, Church S, Savage CJ, et al: Effects of hyperimmune equine plasma on clinical and cellular responses in a low-dose endotoxaemia model in horses. Res Vet Sci 92:40, 2012. PUBMED Abstract
  157. Peek SF, Semrad S, McGuirk SM, et al: Prognostic value of clinicopathologic variables obtained at admission and effect of antiendotoxin plasma on survival in septic and critically ill foals. J Vet Intern Med 20:569, 2006. PUBMED Abstract
  158. Whitlock RH, Buckley C: Botulism. Vet Clin North Am Equine Pract 13:107, 1997. PUBMED Abstract
  159. Liefman CE: Combined active-passive immunisation of horses against tetanus. Aust Vet J 56:119, 1980. PUBMED Abstract
  160. Green SL, Little CB, Baird JD, et al: Tetanus in the horse: a review of 20 cases (1970 to 1990). J Vet Intern Med 8:128, 1994. PUBMED Abstract
  161. Messer NT 4th, Johnson PJ: Serum hepatitis in two brood mares. J Am Vet Med Assoc 204:1790, 1994. PUBMED Abstract
  162. Fernandes I, Lima EX, Takehara HA, et al: Horse IgG isotypes and cross-neutralization of two snake antivenoms produced in Brazil and Costa Rica. Toxicon 38:633, 2000. PUBMED Abstract
  163. Dwyer JM: Immunoglobulins in autoimmunity: history and mechanisms of action. Clin Exp Rheumatol Suppl 15:S3, 1996. PUBMED Abstract
  164. Bleeker WK, Teeling JL, Hack CE: Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect. Blood 98:3136, 2001. PUBMED Abstract
  165. Rouger P: Transfusion induced immunomodulation: myth or reality? Transfus Clin Biol 11:115, 2004. PUBMED Abstract
  166. Kirkley SA: Proposed mechanisms of transfusion-induced immunomodulation. Clin Diagn Lab Immunol 6:652, 1999. PUBMED Abstract
  167. Pfadt E, Carlson DS: Transfusion-associated graft-versus-host disease. Nursing 35:88, 2005. PUBMED Abstract
  168. Parshuram C, Doyle J, Lau W, et al: Transfusion-associated graft versus host disease. Pediatr Crit Care Med 3:57, 2002. PUBMED Abstract
  169. Allison AC: Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology 47:63, 2000. PUBMED Abstract
  170. Suthanthiran M, Morris RE, Strom TB: Immunosuppressants: cellular and molecular mechanisms of action. Am J Kidney Dis 28:159, 1996. PUBMED Abstract
  171. Czock D, Keller F, Rasche FM, et al: Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 44:61, 2005. PUBMED Abstract
  172. Peroni DL, Stanley S, Kollias-Baker C, et al: Prednisone per os is likely to have limited efficacy in horses. Equine Vet J 34:283, 2002. PUBMED Abstract
  173. Rush BR, Worster AA, Flaminio MJ, et al: Alteration in adrenocortical function in horses with recurrent airway obstruction after aerosol and parenteral administration of beclomethasone dipropionate and dexamethasone, respectively. Am J Vet Res 59:1044, 1998. PUBMED Abstract
  174. Giguère S, Viel L, Lee E, et al: Cytokine induction in pulmonary airways of horses with heaves and effect of therapy with inhaled fluticasone propionate. Vet Immunol Immunopathol 85:147, 2002. PUBMED Abstract
  175. Robinson NE, Jackson C, Jefcoat A, et al: Efficacy of three corticosteroids for the treatment of heaves. Equine Vet J 34:17, 2002. PUBMED Abstract
  176. Mair TS, Taylor FG, Hillyer MH: Autoimmune haemolytic anaemia in eight horses. Vet Rec 126:51, 1990. PUBMED Abstract
  177. Vandenabeele SI, White SD, Affolter VK, et al: Pemphigus foliaceus in the horse: a retrospective study of 20 cases. Vet Dermatol 15:381, 2004. PUBMED Abstract
  178. Pusterla N, Watson JL, Affolter VK, et al: Purpura haemorrhagica in 53 horses. Vet Rec 153:118, 2003. PUBMED Abstract
  179. De Bosscher K, Vanden Berghe W, Haegeman G: Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J Neuroimmunol 109:16, 2000. PUBMED Abstract
  180. Franchimont D: Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies. Ann NY Acad Sci 1024:124, 2004. PUBMED Abstract
  181. Barshes NR, Goodpastor SE, Goss JA: Pharmacologic immunosuppression. Front Biosci 9:411, 2004. PUBMED Abstract
  182. Gummert JF, Ikonen T, Morris RE: Newer immunosuppressive drugs: a review. J Am Soc Nephrol 10:1366, 1999. PUBMED Abstract
  183. Messer NT 4th, Arnold K: Immune-mediated hemolytic anemia in a horse. J Am Vet Med Assoc 198:1415, 1991. PUBMED Abstract
  184. Humber KA, Beech J, Cudd TA, et al: Azathioprine for treatment of immune-mediated thrombocytopenia in two horses. J Am Vet Med Assoc 199:591, 1991. PUBMED Abstract
  185. White SD, Maxwell LK, Szabo NJ, et al: Pharmacokinetics of azathioprine following single-dose intravenous and oral administration and effects of azathioprine following chronic oral administration in horses. Am J Vet Res 66(9):1578–1583, 2005. PUBMED Abstract
  186. Saulez MN, Schlipf JW Jr, Cebra CK, et al: Use of chemotherapy for treatment of a mixed-cell thoracic lymphoma in a horse. J Am Vet Med Assoc 224:733, 2004. PUBMED Abstract
  187. Riggott JM, Quarmby WB: Treatment of fibrosarcoma in a horse. Equine Vet J 12:193, 1980. PUBMED Abstract
  188. Espinosa E, Zamora P, Feliu J, et al: Classification of anticancer drugs: a new system based on therapeutic targets. Cancer Treat Rev 29:515, 2003. PUBMED Abstract
  189. Graca L, Le Moine A, Cobbold SP, et al: Antibody-induced transplantation tolerance: the role of dominant regulation. Immunol Res 28:181, 2003. PUBMED Abstract
  190. Kauffman CL, Aria N, Toichi E, et al: A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 123:1037, 2004. PUBMED Abstract
  191. Sigidin YA, Loukina GV, Skurkovich B, et al: Randomized, double-blind trial of anti-interferon-gamma antibodies in rheumatoid arthritis. Scand J Rheumatol 30:203, 2001. PUBMED Abstract